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On 11 March 2020, the World Health Organization de-clared coronavirus disease 2019 (COVID- 19) a pandemic. The presence of underlying cardiovascular disease 
(CVD) confers the highest mortality with COVID- 19. Thus, 
patients with CVD must be considered a particularly at- risk 
population.1–5 Community transmission, patient- to- patient 
transmission and health care worker infection with severe 
acute respiratory syndrome coronavirus 2 (SARS- CoV- 2) are 
overwhelming health services worldwide.4–6 High quality car-
diac care must minimise risk of viral transmission to patients 
and health care workers. It should adapt resources in the con-
text of reduced access to hospital beds and personal protective 
equipment (PPE). This consensus statement reviews and sum-
marises data on SARS- CoV- 2 infection in pre- existing CVD 
and acute cardiovascular manifestations of COVID- 19, and 
makes recommendations for cardiac service provision during 
the pandemic.
Development process for the recommendations
A group of CVD experts, drawn from the Cardiac Society of 
Australia and New Zealand (CSANZ), the Australian and New 
Zealand Society of Cardiac and Thoracic Surgeons, the National 
Heart Foundation of Australia and the High Blood Pressure 
Research Council of Australia, convened in March 2020. Key 
opinion leaders in cardiology, cardiothoracic surgery and public 
health with broad geographic representation were consulted. We 
searched major databases (EMBASE, MEDLINE and PubMed) 
to identify relevant systematic reviews, randomised controlled 
trials and clinical case series in English from January 2020 to 
25 March 2020. As the majority of studies relating to COVID- 19 
and CVD at the time of writing were observational in nature, 
results must be interpreted with caution. Given data limitations, 
consensus documents produced by international cardiology 
societies from December 2019 to March 2020 were reviewed.7–9 
Experts from key areas (electrophysiology and pacing, inter-
ventional cardiology, imaging, cardiothoracic surgery, nursing, 
hypertension, prevention and rural) generated key recommen-
dations from their respective councils and groups. In addition, 
social networking platforms (eg, WhatsApp) involving CSANZ 
board members, cardiology heads of department and key opin-
ion leaders were used to identify relevant resources, guidance 
documents and protocols. An online living document was 
shared to facilitate wide input. The full draft underwent peer 
review by the listed authors as well as external experts in each 
subspecialty field of cardiology before agreement and accept-
ance of the final document.
Pre- existing cardiovascular disease and COVID- 19
Patients with COVID- 19 and pre- existing CVD are at increased 
risk of severe disease and death.1–5 A meta- analysis of eight stud-
ies and over 46  000 patients in China reported that hyperten-
sion, diabetes and CVD were the most common comorbidities.5 
Baseline CVD conferred the highest odds of any comorbidity for 
developing severe versus mild COVID- 19 (odds ratio [OR], 3.42; 
95% CI, 1.88–6.22). Hypertension (OR, 2.36; 95% CI, 1.46–3.83) and 
respiratory disease (OR, 2.46; 95% CI, 1.76–3.44) also increased 
the risk of severe COVID- 19,5 while smoking did not.10 Patients 
with pre- existing CVD had high case fatality rates; five times 
that of the overall COVID- 19 infected population (Box 1).4 In Italy, 
the case fatality rate has been the highest reported worldwide at 
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Abstract
Introduction: The coronavirus 2019 disease (COVID- 19) pandemic is 
caused by severe acute respiratory syndrome coronavirus 2 (SARS- 
CoV- 2). Pre- existing cardiovascular disease (CVD) increases the 
morbidity and mortality of COVID- 19, and COVID- 19 itself causes 
serious cardiac sequelae. Strategies to minimise the risk of viral 
transmission to health care workers and uninfected cardiac patients 
while prioritising high quality cardiac care are urgently needed. We 
conducted a rapid literature appraisal and review of key documents 
identified by the Cardiac Society of Australia and New Zealand 
Board and Council members, the Australian and New Zealand 
Society of Cardiac and Thoracic Surgeons, and key cardiology, 
surgical and public health opinion leaders.
Main recommendations: Common acute cardiac manifestations 
of COVID- 19 include left ventricular dysfunction, heart failure, 
arrhythmias and acute coronary syndromes. The presence of 
underlying CVD confers a five- to tenfold higher case fatality rate 
with COVID- 19 disease. Special precautions are needed to avoid viral 
transmission to this population at risk. Adaptive health care delivery 
models and resource allocation are required throughout the health 
care system to address this need.
Changes in management as a result of this statement: 
Cardiovascular health services and cardiovascular health care 
providers need to recognise the increased risk of COVID- 19 among 
CVD patients, upskill in the management of COVID- 19 cardiac 
manifestations, and reorganise and innovate in service delivery 
models to meet demands. This consensus statement, endorsed by 
the Cardiac Society of Australia and New Zealand, the Australian 
and New Zealand Society of Cardiac and Thoracic Surgeons, the 
National Heart Foundation of Australia and the High Blood Pressure 
Research Council of Australia summarises important issues and 
proposes practical approaches to cardiovascular health care delivery 
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12.8%, with a corresponding high prevalence of baseline CVD in 
fatal cases.11
Pre- existing CVD confers an increased risk of death with 
COVID- 19; health services and patients should therefore take 
additional precautions.
Angiotensin- converting enzyme inhibitors and 
angiotensin receptor blockers
As SARS- CoV- 2 enters cells by binding to human angiotensin- 
converting enzyme 2 (ACE2) receptors found in the lungs and 
heart,12 activation of the renin–angiotensin system may contribute 
to the increased susceptibility to infection in patients with pre- 
existing CVD.13 It has been suggested that angiotensin- converting 
enzyme inhibitors (ACE- I) and angiotensin receptor blockers 
(ARBs) may increase the risk of SARS- CoV- 2 infection or worsen 
the outcome,14 as treatment with ACE- I or ARBs can increase 
the expression and activity of ACE2 in some animal models.15 
However, there is no clinical evidence substantiating an adverse 
effect of ACE- I or ARBs on COVID- 19 outcomes. Conversely, there 
is evidence for protective effects from mouse models,16 and re-
combinant ACE2 and the ARB losartan are currently being tested 
in the United States as potential COVID- 19 therapies.17 An Italian 
case–control study revealed that while ACE- I or ARB use was 
more frequent among COVID- 19 patients owing to higher CVD 
prevalence, they did not influence COVID- 19 severity.18
Given the well established beneficial effects of ACE- I and 
ARBs, we, along with numerous national and international 
societies, strongly recommend that these medications be 
continued.19–21
Acute cardiac injury and COVID- 19
Acute cardiac injury in COVID- 19 manifests as left ventricular 
dysfunction, heart failure, ventricular arrhythmias, electro-
cardiogram (ECG) changes, and elevated B- type natriuretic 
peptide and troponin levels.2,22–24 In the first 41 confirmed 
Chinese COVID- 19 cases, acute cardiac injury defined as el-
evated cardiac biomarkers with ECG changes and left ventric-
ular dysfunction was seen in 12% of patients.2 A later study 
found acute cardiac injury in 19.7% of participants,24 while 
a US study of 21 intensive care unit (ICU) patients described 
cardiomyopathy in 33%.22 Acute cardiac injury was indepen-
dently associated with mortality in hospitalised patients with 
COVID- 19 in China.24
Pathophysiological theories for cardiac injury include direct 
infection of the myocardium with SARS- CoV- 2, myocardial 
inflammation, Takotsubo syndrome and overwhelming multi- 
organ sepsis. While direct viral spread via ACE2 receptors in 
the myocardium has been postulated, a histopathological study 
of COVID- 19- associated cardiomyopathy did not find direct 
SARS- CoV- 2 infection.25 Myocardial inflammatory infiltrates 
were instead seen.26 For patients with left ventricular dysfunc-
tion, ACE- I, ARBs and β- blockers are indicated as the proposed 
pathophysiology of renin–angiotensin system imbalance with 
COVID- 19 points to their potential therapeutic roles. However, 
much more study is needed to define the underlying pathophys-
iology and optimal treatment.
Elevated troponin levels and myocardial infarction
Troponin and other cardiac enzymes are commonly elevated 
in COVID- 19.2,3,5,22,26 Troponin elevation is a prognostic marker 
and may reflect myocarditis or myocardial infarction (MI).27 
The diagnostic implications are unclear as it can be associated 
with non- coronary conditions including acute respiratory infec-
tions28 and type 2 MI.29 Myocardial injury in COVID- 19 patients 
can manifest with ST elevation in the absence of obstructive 
coronary artery disease. Many pathophysiological mechanisms 
have been proposed for COVID- 19- related myocardial injury, 
including myocarditis, microvascular injury or obstruction, en-
dothelial dysfunction and acute plaque rupture. In addition, a 
prothrombotic state has been commonly described with promi-
nent elevations of D- dimer and fibrin/fibrinogen degradation 
products.30–32
In the setting of acute COVID- 19 illness and suspected non- ST 
elevation (NSTEMI), patients who are haemodynamically sta-
ble without ongoing ischaemia may be best managed conserva-
tively, with invasive procedures deferred until after recovery.
Cardiovascular implications of novel therapies
Numerous clinical trials assessing treatment for COVID- 19 are 
being conducted. Chloroquine, hydroxychloroquine, azithromy-
cin and ritonavir–lopinavir are under investigation, alone or in 
combination. These medications can cause cardiac toxicity, spe-
cifically QTc prolongation and torsades de pointes, especially in 
patients with hepatic or renal dysfunction.33
Off- label prescribing of hydroxychloroquine has been reported 
and health professionals should be alert to cardiac toxicity in the 
community.
Recommendations for cardiovascular health care services
Safety is of paramount importance to limit COVID- 19 exposure 
in high risk cardiology patients and our workforce. All patients 
need to be risk assessed for COVID- 19 status to guide appro-
priate infection control measures (Box 2). All health services 
need to review elective procedures in order to increase hospi-
tal capacity and conserve valuable PPE. Alternative health care 
for patients at risk of COVID- 19 that avoids exposure within 
the hospital system requires multidisciplinary assessment. 
Cardiac procedures that require long stays in hospital or the 
ICU should be carefully considered, owing to their impact on 
bed availability. An adaptable threshold for acute cardiology 
admissions and cardiac monitoring is needed. Stable angina, 
troponin- negative chest pain, non- life- threatening arrhyth-
mias or cardiac diagnoses without clinical instability may be 
managed in an outpatient setting. Rapid discharge strategies 
should be instituted, including same- day discharge for elec-
tive percutaneous coronary intervention (PCI), and next- day 
 1 Case fatality rates of patients with COVID- 19 with selected 
comorbidities*
Condition Case fatality rate
Cardiovascular disease 10.5%
Diabetes 7.3%




* Data from 44 672 confirmed COVID- 19 cases from mainland China with an overall case 
















discharge for NSTEMI following revascularisation. As some 
elective procedures or hospital admissions cannot be safely 
postponed, nuanced clinical judgement is required.
Key considerations in the management of acute MI and 
coronary angiography
A critical concern during the COVID- 19 pandemic is use of the 
cardiac catheterisation laboratory (Box 3). Bringing a COVID- 
19- positive patient to the cardiac catheterisation laboratory ex-
poses staff to the risk of infection, and prevents post- procedure 
laboratory use pending a terminal clean. Delays are to be ex-
pected with primary PCI to allow for COVID- 19 assessment and 
infection control measures. ST elevation MI (STEMI) protocols 
from China and the US during the COVID- 19 pandemic have 
been published.23,29 The Sichuan Provincial People’s Hospital 
proposed fibrinolytic therapy for all STEMIs, with suspension 
of their primary PCI service.29 This lysis protocol relied on 
rapid nucleic acid testing, which may be limited by individual 
hospital availability and policy. The US Cardiology Society rec-
ommended primary PCI continuation with appropriate PPE, 
and lysis for select cases.23 In Australia, each health care ser-
vice will be different, but it is important that a local protocol is 
developed and adapted (Box 4), with CSANZ guidance avail-
able.34 Training in PPE, sourcing fibrinolytic medications and 
updating lysis protocols are critical. As COVID- 19 is associated 
with STEMI mimickers (ST elevation without obstructive coro-
nary artery disease due to microvascular thrombosis or myo-
carditis), use of lysis may confer risk without benefit in some 
cases, exacerbated by COVID- associated coagulation abnormal-
ities.17,30 Bedside echocardiography to ascertain regional wall 
abnormalities and computed tomography coronary angiogra-
phy to limit cardiac catheterisation laboratory staff exposure 
could all be considered.
Reliance on the presence of an elevated troponin level to indi-
cate NSTEMI in COVID- 19 patients will be misleading. Greater 
emphasis should be given to high risk clinical features such as 
recurrent chest pain, dynamic ischaemic ECG changes, heart 
failure, haemodynamic instability, major arrhythmias and re-
gional wall motion abnormalities. It is reasonable to defer inva-
sive investigations in stable COVID- 19- positive patients without 
high risk features.
Regional and remote cardiovascular services
In Australia, established pre- hospital lysis programs currently 
exist, with cardiologist- led 24/7 ECG- reading service and pre- 
hospital/small hospital lysis for STEMI where PCI access is 
limited. Patients are then transferred to a PCI- capable hospital. 
These transfers will require additional screening for COVID- 19. 
A greater level of cardiologist- led telehealth support for regional 
and rural centres will be needed. Centralised ECG- reading ser-
vices are well placed to coordinate transfer logistics with linked 
calls between cardiologists and state retrieval, emergency and 
ICU consultants, balancing patient needs with staff safety and 
resource utilisation. It is important to continue to provide STEMI 
services for non- COVID- 19 rural and regional patients already at 
a disadvantage in terms of cardiovascular outcomes, while bal-
ancing the enormous resourcing demands that COVID- 19 places 
on health care systems.
Cardiothoracic surgery considerations
On 25 March 2020, the Australian government suspended non- 
urgent surgery (https://www.pm.gov.au/media/ elect ive-surge 
ry#:~:text=The%20Nat ional %20Cab inet%20is%20act ing,will%20
con tinue %20unt il%20fur ther%20notice). This suspension was 
lifted on 27 April 2020, with non- urgent surgery allowed, at a 
reduced capacity (https://www.health.gov.au/news/austr alian-
health-prote ction-princ ipal-commi ttee-ahppc-state ment-on-
resto ration-of-elect ive-surge ry-and-hospi tal-activity). However 
patients with symptomatic disease will continue to present to 
hospital and require inpatient cardiac surgery. Cardiac surgical 
cases are likely to take longer during the COVID- 19 pandemic 
owing to infection control measures, and access to the ICU may 
at times be limited. The multidisciplinary heart team will need 
to consider and adjust thresholds for management of coronary 
artery disease in the event of increased hospital COVID- 19 case 
load. The same applies to surgical aortic valve replacement or 
transcatheter aortic valve implantation for severe symptomatic 
aortic valve stenosis. The inherent risk of the untreated cardio-
vascular condition will need to be weighed against the risk of 
nosocomial infection during hospitalisation and the implica-
tions for ventilator use, bed stay and recovery time. Establishing 
or re- establishing cardiac surgical ICU programs with outcome 
measures equivalent to those of the general ICU35 could be con-
sidered in the future if needed, to free up precious general ICU 
resources.
 2 Assessment of patient risk for COVID- 19
Clinical and radiological risk factors:*
• fever > 37.5°C (patients may have no or low grade fever on 
presentation)
• cough, shortness of breath or sore throat
• any influenza-like symptoms in a health care worker
• contact with a confirmed COVID-19 contact in the past 14 days
• arrival from overseas in the past 14 days
• lymphocyte count < 1.5 x 109/L
• bi-basal ground glass appearance (computed tomography) or bi-basal 
pneumonia (chest x-ray)
* Note: These risk factors may change; check the Australian Government Department of 
Health website at https://www.health.gov.au/news/health-alert s/novel-coron avirus-
2019-ncov-health-alert for updates. ◆
 3 General considerations for catheterisation laboratory use 
during the COVID- 19 pandemic
• Determine the patient’s COVID-19 status (see Box 2): 
▶ when available, consider rapid point-of-care testing; if unable to 
obtain history (eg, intubated patient), consider the patient to be at 
risk
• For all confirmed or suspected COVID-19 cases:
▶ patients: surgical/medical mask if not intubated
▶ all catheterisation laboratory staff: personal protective equipment 
including aerosol protection (N95 mask), given risk of emergent 
intubation/cardiopulmonary resuscitation/vomiting in ST elevation 
myocardial infarction (aerosol-generating procedures)
• Patients approaching or requiring intubation should receive this before 
transfer to the cardiac catheterisation laboratory, as intubation/suction/
active cardiopulmonary resuscitation all increase aerosolisation of 
respiratory secretions
• Designate “dirty” COVID-19 catheterisation laboratories within each 
institution that are cleared of non-essential equipment and stock to 
facilitate cleaning. Consider dedicated laboratory stock for COVID-19 
patients
• Limit the number of staff in the cardiac catheterisation laboratory to 
essential personnel (eg, cardiologist, scrub assistant, scout nurse)
• Minimise or abolish staff movements in and out of the laboratory during 
the case
• Institute a dedicated “clean” nurse role outside the laboratory to allow 
for passing equipment and medication, coordinate destination teams for 
transfer, and facilitate correct use of personal protective equipment
• A terminal clean following the procedure is required, with potential for 
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Key considerations in imaging and stress testing
During the COVID- 19 pandemic, elective cardiac investigations 
will need to be prioritised, based on short term management 
change versus risk of deferment until the pandemic passes. 
Certain cardiac investigations such as stress testing and tran-
soesophageal echocardiography pose significant viral transmis-
sion risk. Exercise stress testing can result in droplet spread, 
whereas pharmacological testing that obviates the need for exer-
cise or a technician in close proximity may be relatively safer.36 
Transoesophageal echocardiography involves instrumentation 
of the oropharynx, known to harbour the virus with high risk 
of aerosol transmission,37 and should be undertaken only if 
transthoracic echocardiography cannot be performed, or after 
exclusion of COVID- 19. If transesophageal echocardiography 
is performed in a patient with COVID- 19, it should be occur in 
a negative pressure room or with patient intubation with ap-
propriate PPE. General considerations for transthoracic and 
transoesophageal echocardiography for patients with suspected 
or confirmed COVID- 19 are summarised in Box 5.
Acute cardiac care and cardiopulmonary resuscitation
In COVID- 19 cases with concomitant heart failure and hypoxae-
mia, non- invasive ventilation such as continuous positive airway 
pressure and bilevel positive airway pressure is aerosol generat-
ing and not recommended.37,38 High flow nasal oxygen can be 
used within single rooms or shared COVID- 19 ward spaces with 
strict attention to staff safety and the lowest flow necessary to 
maintain oxygen saturation ≥ 92%. Cardiopulmonary resuscita-
tion is another important consideration, currently under review 
by the Australian National COVID- 19 Taskforce. Defibrillation is 
not aerosol generating but all other resuscitative procedures are, 
and PPE is therefore recommended.39 Ways to reduce COVID- 19 
transmission during cardiopulmonary resuscitation include cov-
ering the patient’s mouth and nose with a mask, towel or plastic 
cover, and using mechanical compression devices. Discussion of 
goals of care remains important in both the inpatient and com-
munity setting. Management of hypoxaemia and cardiac arrest in 
patients with suspected or confirmed COVID- 19 is summarised 
in Box 6.
 4 General principles to consider for management of ST elevation myocardial infarction (STEMI) during the COVID- 19 pandemic
CTCA = computed tomography coronary angiography; PCI = percutaneous coronary intervention; PPCI = primary PCI; PPE = personal protective equipment. Note: At any stage in this path-
way either PPCI or thrombolysis could be considered. ◆
 5 General considerations for transthoracic and transoesopha-
geal echocardiography for patients with suspected or 
confirmed COVID- 19
• Personal protective equipment for health care providers and assistants 
performing the test
• Shorten study duration to reduce face-to-face contact; eg, limiting 
transthoracic echocardiography to 15 minutes
• Dedicated COVID-19 machine and equipment
• Perform test in patient’s room; do not bring patient to the cardiology 
department
• Plastic disposable covers for the machine and equipment, removed 
inside the room on completion, followed by complete clean of 
equipment with alcohol
• Consider hand-held or portable echocardiography if available
• Transoesophageal echocardiography has high risk for respiratory 
transmission and should be performed only if result will change 
treatment, in negative pressure room or designated theatre space
• Exercise electrocardiography and exercise stress echocardiography 
have high respiratory transmission risk and suspension of these services 
should be carefully considered
 6 Management of hypoxaemia and cardiac arrest in patients 
with suspected or confirmed COVID- 19
• Continuous positive airway pressure and bilevel positive airway 
pressure are aerosol generating and should be avoided
• High flow nasal oxygen can be used in single rooms or shared COVID-19 
ward spaces with appropriate staff protection
• For resuscitation:
▶ cover the patient’s mouth and nose (mask, towel or other cover)
▶ early defibrillation is life saving and not considered aerosol 
generating
▶ chest compressions, assisted ventilation and advanced airway 
manoeuvres are considered aerosol generating (weak level of 
evidence)39 and personal protective equipment should be worn
▶ use mechanical compression devices if available
















Key considerations in electrophysiology and pacing services
The COVID- 19 pandemic poses particular challenges in car-
diac arrhythmia management, as patients require outpatient 
clinic review, ambulatory monitoring, electrophysiological in-
terventions, implantation and follow- up of cardiac implanted 
electronic devices (Box 7). A team- based approach is advised, 
with teleconferences at weekly intervals to ensure maintenance 
of  appropriateness criteria, urgency, and alignment of practices 
with the local outbreak response.
Considerations for outpatient cardiology care and use of 
telehealth
Strategies to minimise COVID- 19 exposure in cardiovascular 
outpatient clinics must be adopted, including government rec-
ommendations for physical distancing. Serious consideration 
should be given to using telehealth for all outpatient consul-
tations. For in- person consultations, verbal and temperature 
screening and social distancing are required. Administrative 
teams should be supported in their ability to maintain physi-
cal distancing to reduce their own exposure. Nurse- led clin-
ics and cardiac rehabilitation programs will need to adapt 
by using telehealth or digital health platforms. Patients can 
be monitored and supported at home remotely, ensuring 
adequate medication supply, using a set of scales and blood 
pressure machines to titrate medications. Online support can 
enable patients to continue cardiac rehabilitation during home 
isolation.
Considerations for primary care and cardiovascular disease 
in the community
The importance of maintaining contact with patients by primary 
care physicians is highlighted by trends showing an unintended 
consequence of COVID- 19 is less frequent primary care and de-
layed hospital presentations. The National Heart Foundation has 
released public health messages emphasising the importance of 
medication continuation and staying connected to treating doc-
tors, and that it is both safe and beneficial to present to hospital 
if required.40
Health care workers
There is a considerable risk of SARS- CoV- 2 infection among 
health care workers.4,6 Health care services need to ensure ad-
equate protection with appropriate PPE in the care of COVID- 19 
patients. This includes fitted respirator masks (N95, FFP2 or 
equivalent) for any aerosol- generating procedures, and train-
ing in correct PPE use. Services may need to adapt to health 
care worker shortages and leave due to illness or quarantine. 
Cardiology trainees may also be affected by re- allocation 
within the hospital. The decision to move to a weekly rotation 
of staggered cardiology teams (relevant for clinicians, surgeons, 
sonographers and STEMI on- call teams) may limit infection of 
all staff if case numbers rise. Links to relevant documents and 
important websites are provided in the Supporting Information.
Conclusion
The COVID- 19 pandemic is constantly evolving, and we must 
both prepare for and adapt to this global health care crisis. 
Cardiology services and providers need to develop and refine 
COVID- 19 strategies according to the level of community in-
fection and in line with both local hospital and governmental 
policy.
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7 General considerations for electrophysiology and pacing 
during the COVID- 19 pandemic
• For cardiac implanted electronic device follow-up:
▶ avoid in-person clinics, hospitals and office visits
▶ use remote monitoring/telehealth
▶ for major problems (eg, lead/battery or device therapies in 
defibrillator patients), consider risks of delayed visit versus risk of 
COVID-19 exposure
• Requests for urgent cardiac implanted electronic device interrogation 
by wards and emergency departments:
▶ use remote monitoring and/or manual transmissions
▶ face-to-face interrogation requires use of personal protective 
equipment and minimal number of technicians with wireless 
technology if possible
• Defer elective electrophysiology procedures for 1–3 months until 
personal protective equipment stocks are sufficient
• Urgent procedures to be continued: pacemaker for atrioventricular 
block and asystolic pauses; generator change for pacing dependent 
patients; secondary prevention defibrillators; catheter ablation in 
selective patients with ventricular tachycardia storm; lead extraction as 
determined by specialist centres
• Avoid ambulatory monitoring due to low yield; consider mail-out mobile 
electrocardiogram monitors
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